Health ❯ Healthcare ❯ Chronic Conditions

Type 2 Diabetes

Management Strategies Weight Management Treatment Options Medication Management Weight Loss Medications Hypertension GLP-1 Medications Monitoring and Management Diabetes Management GLP-1 Hormones Insulin Sensitivity Medication Usage Insulin Therapy Atherosclerotic Cardiovascular Disease Potential Treatments Obesity and Diabetes GLP-1 Drugs Management and Treatment GLP-1 Receptor Agonists GLP-1 Agonists Medication Treatments Treatment Discontinuation CagriSema Treatment Semaglutide Use Obesity Management Insulin Resistance Medication Access GLP-1 Drug Usage Obesity

Meta-Analysis Finds Tirzepatide Produces Largest Average Weight Loss Among FDA‑Approved GLP‑1s

Linked to dual GLP‑1/GIP targeting, tirzepatide showed larger average weight loss in trials with uncertain post‑treatment durability.

Cigna Drops GLP-1 Weight-Loss Coverage for Its Employees

FDA Approves Awiqli, First Once-Weekly Basal Insulin for Type 2 Diabetes

Heart Risks Rebound After GLP-1 Breaks, New Data Show Continuous Use Is Safest

Vanderbilt Study Maps 70 Conditions That Precede Alzheimer’s by a Decade

Novo Nordisk Files FDA Application for Weekly CagriSema Obesity Shot as GLP-1 Competition Intensifies

Lilly Taps Walmart for First Retail Pickup of Discounted Zepbound Vials Starting Mid-November

EMA Approves Cardiovascular Indication for Novo Nordisk’s Rybelsus

UK Regulator Probes Pancreatitis Cases Tied to GLP-1 Weight-Loss Therapies